EMPOWERING PROGRESS: ONCOLOGY CLINICAL TRIALS SPOTLIGHT

Patritumab deruxtecan (HER3-DXd) in active brain metastases from metastatic breast and non-small cell lung cancers, and leptomeningeal disease from advanced solid tumors: The TUXEDO-3 phase II trial.

Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial

The impact of decision tools during oncological consultation with lung cancer patients: A systematic review within the I3LUNG project

Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: the OPHELIA phase 2 study

Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial

ABIGAIL: Randomized phase II study of abemaciclib plus endocrine therapy (ET) with or without a short course of induction paclitaxel in patients (pts) with previously untreated HR-positive/HER2-negative advanced breast cancer (HR+/HER2- ABC) with aggressive disease criteria

A multicenter, open-label, single-arm, multicohort phase II clinical trial of trastuzumab deruxtecan in human epidermal growth factor receptor 2 (HER2)-positive and HER2-low advanced breast cancer (ABC) with brain metastases and/or leptomeningeal carcinomatosis (LMC) – The DEBBRAH study

Evaluation of HER2DX risk-score in residual disease (RD) from HER2-positive (HER2+) early breast cancer (EBC) patients (pts) following neoadjuvant trastuzumab and pertuzumab (HP)-based therapy: An exploratory analysis from the PHERGain trial

Evaluation of a Generative Artificial Intelligence (AI) and Natural Language Processing (NLP) tool to obtain clinical data from electronic health records (EHRs) versus manual data capture in Oncology Clinical Trials: The MIRROR study.

Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial

Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and
pathological complete response (pCR) in HER2-positive early breast cancer (EBC):
An exploratory analysis of the PHERGain trial

LUZERN: Phase 2 trial of niraparib and aromatase inhibitors (AI) for pretreated hormone receptor-positive/HER2-negative germline BRCA-mutated advanced breast cancerRN: Phase 2 trial of niraparib and aromatase inhibitors (AI) for pretreated hormone receptor-positive/HER2-negative germline BRCA-mutated advanced breast cancer